Total Voting Rights and Share Capital Overview
Understanding a company's voting rights and share capital is essential for investors and stakeholders. Recently, details emerged regarding total voting rights and the state of shares forming the capital for a significant biopharmaceutical company. These updates provide valuable insights into ownership dynamics that can influence investment strategies.
Shares Outstanding: A Snapshot
On the specified date, the company's share capital included a total of 145,951,274 shares outstanding. This significant number indicates the level of company ownership distributed among shareholders. Knowing the number of shares helps investors gauge the impact of their decisions on the company and align their actions based on share distribution.
Voting Rights Breakdown
With respect to voting rights, the data provided shows there are 158,653,570 gross voting rights and 158,594,019 net voting rights. The distinction between gross and net voting rights matters deeply for shareholders. Gross voting rights generally represent theoretical control that encompasses all shares, even those whose rights have been suspended. In contrast, net voting rights reflect the actual votes that can influence decisions at shareholder meetings, excluding shares with suspended voting rights.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company that focuses on developing oral therapies for patients suffering from metabolic diseases, particularly MASH, a chronic liver condition. They are conducting comprehensive research, including pivotal Phase 3 trials of their innovative drug, lanifibranor, aimed at addressing this prevalent health issue. Through their dedication to advancing therapies, they strive to improve patient outcomes significantly.
Corporate Strategies and Future Directions
As a part of their efforts, the company is publicly traded on the Euronext Paris under the ticker IVA. It is also listed on the Nasdaq Global Market, ensuring that they reach a broader audience. This dual listing allows Inventiva to tap into larger pools of investment while enhancing visibility within the biotech sector.
Contact Information for Stakeholders
Communication channels remain open for those interested in further engaging with the company. Pascaline Clerc, the Executive Vice President of Strategy and Corporate Affairs, is available via email and phone for inquiries related to corporate matters. For media relations, professional contacts are also provided for interested parties. This openness exemplifies Inventiva's commitment to transparency and stakeholder engagement.
Frequently Asked Questions
What is the importance of total voting rights?
Total voting rights are crucial as they determine control in shareholder meetings, influencing corporate decisions.
What distinguishes gross voting rights from net voting rights?
Gross voting rights include all shares, while net voting rights consider only those shares eligible for voting, excluding suspended rights.
What is MASH, and why is it significant?
MASH (Metabolic Associated Fatty Liver Disease) is a progressive liver disease affecting many, making effective treatments vital for health improvement.
How can stakeholders reach Inventiva?
Stakeholders can contact Inventiva's corporate affairs via Pascaline Clerc or reach out to media and investor relations accordingly.
Where is Inventiva listed?
Inventiva is listed on the Euronext Paris under ticker IVA and also appears on the Nasdaq Global Market.
